{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:01:00Z","timestamp":1780977660935,"version":"3.54.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107256","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:24:41Z","timestamp":1778970281000},"page":"107256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond neurology: The case for metabolic phenotyping in multiple sclerosis diagnostic frameworks"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7344-638X","authenticated-orcid":false,"given":"Mobeen","family":"Sajjad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7_Suppl_1","key":"10.1016\/j.msard.2026.107256_bib0001","article-title":"Exploring the effect of GLP-1 agonists on Multiple sclerosis disease progression","volume":"104","author":"Ali","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107256_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.107132","article-title":"Beyond the 2024 McDonald criteria for defining and diagnosing multiple sclerosis","volume":"109","author":"Giovannoni","year":"2026","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2026.107256_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2026.1737057","article-title":"Increasing the rigor of body composition and adiposity measurement in multiple sclerosis research","volume":"17","author":"Taylor","year":"2026","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107256_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/pathophysiology33010005","article-title":"Is obesity a modifiable risk factor in multiple sclerosis? Mechanistic insights into neuroinflammation and oxidative damage","volume":"33","author":"Varra","year":"2026","journal-title":"Pathophysiology"},{"key":"10.1016\/j.msard.2026.107256_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200334","article-title":"Obesity affects disease activity and progression, cognitive functioning, and quality of life in people with multiple sclerosis","volume":"12","author":"Wu","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:43:30Z","timestamp":1780976610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":5,"alternative-id":["S2211034826002920"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107256","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond neurology: The case for metabolic phenotyping in multiple sclerosis diagnostic frameworks","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107256"}}